Search research articles
Contact Us
Filters
Showing results (51-60 of 62) with videos related to
Page
of 7
Sort By:
Anticancer Research
|
November 1, 1987
Morphometric study of myocardial changes during puromycin aminonucleoside induced nephropathy in rats
W J van der Vijgh, D Van Velzen, J S Van der Poort, et al.
British Journal of Cancer
|
May 10, 2012
Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study
D Strumberg, M E Scheulen, B Schultheis, et al.
European Journal of Cancer & Clinical Oncology
|
October 1, 1988
Morphometric study of myocardial changes during doxorubicin-induced cardiomyopathy in mice
W J van der Vijgh, D van Velzen, J S van der Poort, et al.
Investigational New Drugs
|
December 21, 2010
Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer
Dirk Strumberg, Beate Schultheis, M E Scheulen, et al.
Seminars in Oncology
|
January 14, 1998
Phase I study of paclitaxel administered as a 1-hour infusion: toxicity and pharmacokinetics
H Maier-Lenz, B Hauns, B Haering, et al.
British Journal of Cancer
|
June 16, 2012
A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network
K Mross, C Dittrich, W E Aulitzky, et al.
Clinical Pharmacology and Therapeutics
|
December 23, 2006
Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics
N F Smith, S Marsh, T J Scott-Horton, et al.
British Journal of Cancer
|
November 28, 2007
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV
S Steinbild, K Mross, A Frost, et al.
British Journal of Cancer
|
November 13, 2008
Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours
D Strumberg, B Schultheis, I A Adamietz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 28, 2004
A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors
K Mross, H Richly, N Schleucher, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 62) with videos related to
Sort By:
Page
of 7
Anticancer Research
|
November 1, 1987
Morphometric study of myocardial changes during puromycin aminonucleoside induced nephropathy in rats
W J van der Vijgh, D Van Velzen, J S Van der Poort, et al.
British Journal of Cancer
|
May 10, 2012
Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study
D Strumberg, M E Scheulen, B Schultheis, et al.
European Journal of Cancer & Clinical Oncology
|
October 1, 1988
Morphometric study of myocardial changes during doxorubicin-induced cardiomyopathy in mice
W J van der Vijgh, D van Velzen, J S van der Poort, et al.
Investigational New Drugs
|
December 21, 2010
Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer
Dirk Strumberg, Beate Schultheis, M E Scheulen, et al.
Seminars in Oncology
|
January 14, 1998
Phase I study of paclitaxel administered as a 1-hour infusion: toxicity and pharmacokinetics
H Maier-Lenz, B Hauns, B Haering, et al.
British Journal of Cancer
|
June 16, 2012
A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network
K Mross, C Dittrich, W E Aulitzky, et al.
Clinical Pharmacology and Therapeutics
|
December 23, 2006
Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics
N F Smith, S Marsh, T J Scott-Horton, et al.
British Journal of Cancer
|
November 28, 2007
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV
S Steinbild, K Mross, A Frost, et al.
British Journal of Cancer
|
November 13, 2008
Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours
D Strumberg, B Schultheis, I A Adamietz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 28, 2004
A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors
K Mross, H Richly, N Schleucher, et al.
Page
of 7